Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 July 2014Website:
http://marinuspharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:31:39 GMTDividend
Analysts recommendations
Institutional Ownership
MRNS Latest News
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=89206&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / July 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=89155&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , July 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 5, 2024.
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=89222&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=89112&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=89110&wire=1 or contact Joseph E. Levi, Esq.
Shareholders with losses of $100,000 or more are encouraged to contact the firm. LOS ANGELES , July 3, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS).
LOS ANGELES , July 3, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 5, 2024.
What type of business is Marinus Pharmaceuticals?
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
What sector is Marinus Pharmaceuticals in?
Marinus Pharmaceuticals is in the Healthcare sector
What industry is Marinus Pharmaceuticals in?
Marinus Pharmaceuticals is in the Biotechnology industry
What country is Marinus Pharmaceuticals from?
Marinus Pharmaceuticals is headquartered in United States
When did Marinus Pharmaceuticals go public?
Marinus Pharmaceuticals initial public offering (IPO) was on 31 July 2014
What is Marinus Pharmaceuticals website?
https://marinuspharma.com
Is Marinus Pharmaceuticals in the S&P 500?
No, Marinus Pharmaceuticals is not included in the S&P 500 index
Is Marinus Pharmaceuticals in the NASDAQ 100?
No, Marinus Pharmaceuticals is not included in the NASDAQ 100 index
Is Marinus Pharmaceuticals in the Dow Jones?
No, Marinus Pharmaceuticals is not included in the Dow Jones index
When does Marinus Pharmaceuticals report earnings?
The next expected earnings date for Marinus Pharmaceuticals is 09 August 2024